![]() We observed significant correlations between a reduction in hsCRP with increases in LDL (r=0.25,p=0.02, Figure 1a), HDL (r=0.23, p=0.03), apoA1 (r=0.27, p=0.01 and HDL cholesterol efflux capacity (r=0.24, p=0.02), an overall improvement of efflux capacity of 5.7% (p=5x10 -4, Figure 1b).Ĭonclusion: Reduction in inflammation was associated increased LDL levels, and concomitant increases in HDL, ApoA1, and improvements in HDL cholesterol efflux capacity. We studied 90 RA subjects, mean age 57 years, 89% female, all subjects were on disease modifying anti-rheumatic drugs median baseline hsCRP was 28.6mg/L and follow-up 4.3 mg/L (reduction of 85%, p<0.0001). We determined the correlations between reduction in hsCRP and change in lipid parameters using the Pearson test. We measured total cholesterol (TC), LDL, high density lipoprotein (HDL), apolipoprotein B (apoB), apoA1, and HDL cholesterol efflux capacity at baseline and one year follow-up. ![]() Subjects on statins during the study period or 6 months prior were excluded. We included subjects with hsCRP reduction ≥10mg/L at two time points one year apart. Methods and Results: We conducted this study in a longitudinal RA cohort from a large academic center. The objective of this study was to determine the longitudinal association between changes in inflammation with advanced lipoprotein measurements and HDL cholesterol efflux capacity. This apparent paradox may be explained by favorable changes in other lipid measurements. ![]() Customer Service and Ordering Informationīackground: Potent anti-inflammatory RA treatments are associated with reduced cardiovascular (CV) risk as well as increases in low density lipoprotein (LDL).Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |